Global Leaders in Patented HOCI Formulations & Technologies
SpectrumX are leaders in patented formulations of HOCl (Hypochlorous Acid). Through our partnership with Spectrum Antimicrobials, California, USA we hold various licenses for the use of their unique formulations in the United Kingdom and Europe.
Historically HOCl has been overlooked by “big pharma” due to the fact HOCl has never previously been able to be patent protected as well as the limitation of traditional production methods. Both of these challenges have been overcome by SpectrumX.
Hypochlorus Acid (HOCI)
HOCl has almost limitless potential applications, it is one of the most effective biocides known to man. It eradicates all bacteria, mycobacteria, spores, fungi, viruses – including COVID-19 – within 15 seconds. It is 300 times stronger than bleach yet is 100% safe for human use. The substance is produced by white blood cells to fight infection in the body and it is the reason humans have evolved over millions of years.
Through our partnership with Spectrum Antimicrobials, California, USA we hold various licenses for the use of their unique formulations in the United Kingdom and Europe. Historically HOCl has been overlooked by “big pharma” due to the fact HOCl has never previously been able to be patent protected as well as the limitation of traditional production methods.
This all changed with the development of their PKU development platform – Spectricept. Spectrum Antimicrobials are the only company in the world to hold a patent on a finished HOCl product. They additionally have created a formulation that not only has excellent shelf life but additionally maintains efficacy in the presence of serum (blood, salvia, dirt etc). This is key because the product works in real world conditions where all other HOCl producers fail.
Scientific Innovation – Spectricept
Spectricept – has been 30 years in development as a medical-grade solution and is now available to protect the public exclusively through SpectrumX’s sanitising products and POD technology.
- The Spectricept solution is 300 times more effective than
bleach in killing pathogens but 100% human safe. - Is the only effective formulation of HOCl (Hypochlorous Acid)
ever created for use in “real world” conditions. - When used in conjunction with masks and social distancing will
offer the highest degree of public safety available for mass gatherings.
SpectrumX Pre-IPO Raise
This Pre-IPO offering outlines the opportunities for the commercialisation of novel formulations of HOCL in the healthcare and pharmaceutical markets. Specifically how the SpectrumX Group can positively impact these sectors, through a diversified portfolio of offerings, by exploiting licenses from Spectrum Antimicrobials Inc., of the world’s first and only patent-protectable formulations of HOCL (Hypochlorous Acid).
The company is focused on bringing to market a groundbreaking respiratory therapy (SPC-069) and the roll out of the most powerful hand sanitiser in the world (Spectricept™). Both products utilise unique patent pending HOCL formulations.
To date in excess of £10 million has been invested by existing shareholders and Convertible Loan Note (CLN) holders.
Pre-IPO capital is currency being raised at a discount to an initial listing price on the London Stock Exchange, target listing date is end of Q1 2022. Conservative estimated entry valuation is £50m.
SpectrumX have appointed Alfred Henry, a leading corporate advisory firm for companies listing on the London Stock Exchange. They are a specialist advisory firm who advise companies looking to list in the biotech sector.
Share Registrars Limited has been appointed as both registrars and receiving agent to the Company and will hold application monies until loan note certificates are issued on the register of loan note holders. Share Registrars was founded as a registrar and receiving agent in 2003 and is registered with the Financial Conduct Authority under the Anti Money Laundering Regulations.
They have been selected by SpectrumX due to their good standing in the financial services market as well as their experience in the sector.
Capital raised will be deployed to support the following key areas:
- Further supporting clinical trials – 35%
- Registration of pharmaceutical product with EMA – 15%
- Registration of pharmaceutical product with MHRA – 10%
- Construction of UK production facility including clean rooms – 20%
- Supporting launch of UK products – 5%
- Expanding professional team – 10%
- Testing on HOCL for other medical applications – 10%
REQUEST INVESTMENT OFFERING HERE
- Spectrum X executive team present late Spring listing plans
- UK Investor Magazine podcast with Alan Green covering Lloyds #LLOY, GlaxoSmithKline #GSK and two IPOs Lift Global Ventures #LFT and SpectrumX #SpecX
- Alan Green discusses SpectrumX, #AEXG AEX Gold, #AAF Airtel Africa & #ECR ECR Minerals on the Vox Market Podcast
- Evening Standard – It’s Time To Switch Your Hand Sanitiser – Spectriskin
- SpectrumX Appoints Chief Financial Officer and Non-Executive Director
- SpectrumX Pre-IPO Raise
- SpectrumX CEO Damien Hancox joins Proactive Katie Pilbeam in the London studio to talk about the SPC-069 treatment
